期刊文献+

基质金属蛋白酶-9与脑缺血损伤的关系研究进展 被引量:10

New development of relationship of atrixmetallo proteinases-9 (MMP-9) and cerebral ischemia
下载PDF
导出
摘要 基质金属蛋白酶-9(MMP-9)能降解和重塑造细胞外基质,破坏血—脑屏障,导致脑损伤和脑水肿。了解MMP-9在脑缺血再灌注损伤中的作用、表达、影响其表达的因素及有关抗体的研究及应用,可以为脑梗死的早期诊断、预防和治疗开辟新的途径。 Matrix metalloproteinases-9 (MMP-9) can degrade and remode extracelluar matrix, destruct the blood-brain barrier. These led to the cerebral injury and brain edema. Understanding of the expression and role of MMP-9, the factor affecting its expression and the application of MMP-9 antibody during cerebral ischemic/repeffusion injury is important. It can find new appraches in the early diagnosis, prevention, and treatment.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2007年第5期565-568,共4页 China Journal of Modern Medicine
关键词 基质金属蛋白酶-9 脑缺血 matrix metalloproteinases-9 cerebral ischemia
  • 相关文献

参考文献23

  • 1MANDAL M,MANDAL A,DAS S,et aL Clinical implications of matrix metalloproteinases[J].Mol Cell Biochem,2003,252(1-2):305-329.
  • 2张卫强,林华,周勇安,王云杰.基质金属蛋白酶-2和基质金属蛋白酶-9在非小细胞肺癌组织中的表达及临床意义[J].中国现代医学杂志,2006,16(6):833-835. 被引量:20
  • 3王文祥,肖高明,文继舫.CD44、基质金属蛋白酶及其抑制剂与肿瘤浸润和转移[J].中国现代医学杂志,2005,15(5):712-715. 被引量:11
  • 4HAMACHER S,MATERN S,ROEB E.Extracellular matrix from basic research to clinical significace.An overview with specialconsideration of matrix metalloproteinases[J].Dtsch Med Wochenschr,2004,129(38):1976-1980.
  • 5CHAKRABORTI S,MANDAL M,DAS S,et al.Regulation of matrix metalloproteinases:an overview[J].Mol Cell Biochem,2003,253(12):269-285.
  • 6WAGNER S,NAGEL S,KLUGE B,et al.Topographically graded postischemic presence of metalloproteinases is inhibited by hypothermia[J].Brain Res,2003,984(1-2):63-75.
  • 7MAIER CM,HSIEH L,YU F,et al.Matrix metalloproteinase-9 and myeloperoxidase expression:quantitative analysis by antigen immunohiatochemistry in a model of transient focal cerbral ischemia[J].Stroke,2004,35(5):1169-1174.
  • 8KALELA A,PONNIO M,KOIVU T A,et al.Association of serum sialic acid and MMP-9 with lipids and inflammatory markers[J].Eur J Clin Invest,2000,30:99-104.
  • 9PLANAS AM,SOLE S,JUSTICIA C,et al.Expresaion and actiation of matrix metalloproteinnses-2 and-9 in rat brain after transient cerebral focal ischemia[J].Neurobiol Dis,2001,8:834-846.
  • 10GURSOY-OZDEMIR Y,QIU J,MATSUOKA N,et al.Cortical spreading depression activates and upregulates MMP-9[J].Clin Invest,2004,113:1447-1455.

二级参考文献22

  • 1刘建平.非随机研究的系统评价方法(一)[J].中国循证医学,2001,1(4):239-243. 被引量:73
  • 2MINGShu-hong,SUNTie-ying,XIAOWei,XUXiao-mao.Matrix metalloproteinases-2,-9 and tissue inhibitor of metallo-proteinase-1 in lung cancer invasion and metastasis[J].Chinese Medical Journal,2005(1):69-72. 被引量:14
  • 3Hacke W, Kaste M, Fieschi C, et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for actue hemispheric stroke. JAMA, 1995, 274(13): 1017-1025.
  • 4The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for actue ischemic stroke. N Engl J Med, 1995, 333(24): 1581-1587.
  • 5The Multicenter Acute Stroke TrialEurope Study Group. Thrombolytic therapy with Streptokinasein acute ischemic stroke. N Engl J Med, 1996, 335(3): 145-150.
  • 6Rosenberg GA, Navratil M, Barone F, et al. Proteolytic casecade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Metab, 1996, 16(3): 360-366.
  • 7Gasche Y, Fujimura M, Morita- Fujimura Y, et al. Early appearance of activated matrix metalloprotienase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfuntion. J Cereb Blood Metab, 1999, 19(9): 1020-1028.
  • 8Castellanos M, Leila R, Serena J, et al. Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke. Stroke, 2004, 35(7): 1671-1676.
  • 9Montaner J , Molina CA, Monasterio J , et al . Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke. Circulation, 2003, 107(4): 598-603.
  • 10Montaner J, Fernández-Cadenas I, Molina CA, et al. Safety Profile of Tissue Plasminogen Activator Treatment Among Stroke Patients Carrying a Common Polymorphism (C-1562T) in the Promoter Region of the Matrix Metalloproteinase-9 Gene. Stroke, 2003, 34(12): 2851-2855.

共引文献34

同被引文献78

引证文献10

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部